Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 2
2005 1
2006 2
2007 1
2008 2
2009 2
2010 2
2011 2
2012 3
2019 1
2020 2
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, Stahel RA. Homicsko K, et al. Among authors: fisher p. J Immunother Cancer. 2023 Oct;11(10):e007585. doi: 10.1136/jitc-2023-007585. J Immunother Cancer. 2023. PMID: 37880184 Free PMC article.
Non-small cell lung cancer.
Hill A, Fisher P, Yeomanson D. Hill A, et al. Among authors: fisher p. BMJ. 2012 Sep 27;345:e6443. doi: 10.1136/bmj.e6443. BMJ. 2012. PMID: 23044990 No abstract available.
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, Stahel RA. Banna GL, et al. Among authors: fisher p. Lung Cancer. 2022 Jul;169:77-83. doi: 10.1016/j.lungcan.2022.05.018. Epub 2022 May 28. Lung Cancer. 2022. PMID: 35660972 Clinical Trial.
Oral presentation of malignant mesothelioma.
Murray LJ, Higham J, Suvarna SK, Craig GT, Bridgewater CH, Fisher PM, Thornhill MH. Murray LJ, et al. Among authors: fisher pm. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Jan;111(1):e21-6. doi: 10.1016/j.tripleo.2010.05.009. Epub 2010 Sep 1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011. PMID: 20813558
The Development of a Multi-Modal Cancer Rehabilitation (Including Prehabilitation) Service in Sheffield, UK: Designing the Active Together Service.
Humphreys L, Myers A, Frith G, Thelwell M, Pickering K, Mills GH, Kerr K, Fisher P, Kidder J, Keen C, Hodson S, Phillips G, Smith R, Evans L, Thornton S, Dale E, Maxwell L, Greenfield DM, Copeland R. Humphreys L, et al. Among authors: fisher p. Healthcare (Basel). 2024 Mar 29;12(7):742. doi: 10.3390/healthcare12070742. Healthcare (Basel). 2024. PMID: 38610164 Free PMC article.
26 results